74 results about "Psychotic illness" patented technology

The present application relates to a sustained release delivery composition of a vesicular monoamine transporter type 2 (VMAT2) inhibitor, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of hyperkinetic movement disorders including, but not limited to, tardive dyskinesia (TD), Huntington's disease (HD) chorea, tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. The present application also relates to a sustained release delivery composition of an antipsychotic agent, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of schizophrenia, bipolar disorder, and other psychiatric diseases or disorders. The method of making or using the composition is also disclosed.

The disclosure provides methods for the for treatment of psychosis, such as schizophrenia, or depression (such as bipolar depression) and / or anxiety, comprising administering to a patient in need thereof, (i) a 5-HT2A or 5-HT2A / D2 receptor ligand, for example a substituted heterocycle fused gamma-carboline as described herein, in free, pharmaceutically acceptable salt or prodrug form, and (ii) a nitric oxide donor, separately (sequentially or simultaneously), or in combination (e.g., in a fixed dose combination).

The invention provides a microbial marker and a prediction model for schizophrenia with social anxiety disorder. The microbial marker is a Bacteroides microorganism in saliva. The relevance between the relative abundance of Bacteroides microorganisms in saliva and social anxiety disorder is found for the first time. A Nomogram clinical prediction mode is formed by taking the specific microbial marker as a microbial marker in combination with a children bad experience scale and 6-hydroxymelatonin and 5-hydroxyindoleacetic acid in serum, so that objective biological indexes can be provided for early diagnosis and monitoring of whether schizophrenia is accompanied by social anxiety disorder or not; errors of subjective evaluation are reduced; moreover, the oral saliva sample has the obvious advantage of being easy to collect for psychiatric patients, the working difficulty of medical staff can be greatly reduced, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia accompanied with social anxiety disorder are expected to be brought.

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

A method for treating a mental disorder in a subject, comprising the step of normalizing the expression of both DRD1 and DRD5 belonging to the DRD1-like family of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting the upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using antipsychotic drugs that directly target the DRD1 / 5 promoter. The antipsychotic drugs used are typical and / or atypical antipsychotic drugs such as haloperidol, risperidone, clozapine, and cariprazine. This treatment is also useful for subjects in whom the constitutive expression of the DRD1 / 5 gene is impaired. This method can be used to treat schizophrenia, autism, depression, mania, and bipolar disorder by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparing with a standard sequence database.

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

The invention relates to a cancer patient mental health prediction model based on multi-source data and application. The model comprises the following steps: utilizing electronic health record (EHR) data and longitudinal data of cancer patients in prospective queue research; constructing and verifying a prediction model in combination with multiple factors; carrying out model training and verification by utilizing a machine learning algorithm so as to realize early prediction of anxiety, depression and psychotic disorders; and quantifying the contribution of each factor to the psychological health risk through model interpretive analysis. Through multi-source data fusion and an advanced algorithm, the early recognition rate of the psychological health problem of the cancer patient can be effectively improved, resource waste and diagnosis delay are reduced, and the treatment effect and life quality of the patient are improved.

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and / or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

The invention relates generally to improvements in the treatment of psychotic symptoms, and more particularly, to improvements in the identification of an individual or a population of individuals for whom treatment with iloperidone, an iloperidone metabolite, or pharmaceutically-acceptable salts thereof may provide a particular benefit in treating an individual's psychotic symptoms based on the individual's genotype at the PPEF2 locus.

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

Compositions and methods for treating psychosis or a psychotic disorder with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of psychosis or a psychotic disorder. Formula (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

The present invention relates to the field of chemical medicine, and provides a compound represented by Formula I, which acts on 5-HT 2A and 5-HT 2C receptors, and has a selectivity for 5-HT 2A superior to or similar to pimavanserin. It is used for the treatment of schizophrenia or behavioral disorders and psychosis related to Parkinson's disease and dementia. The antipsychotic activity of the compound of the present application is equivalent to that of pimavanserin, and its cardiotoxicity is less than that of pimavanserin.

The invention provides a microbial marker for schizophrenia with social anxiety disorder and application of the microbial marker. The microbial marker is a deinococcus microorganism in saliva. The relevance between the content of the deinococcus microorganisms in saliva and social anxiety disorder is found for the first time. Moreover, by taking deinococcus microorganisms in saliva as potential microbial markers, objective biological indexes can be provided for early diagnosis and monitoring of the schizophrenia accompanied with social anxiety disorder, and errors of subjective evaluation are reduced; moreover, compared with the intestinal specific biomarker, the oral saliva sample has the obvious advantages of easiness in collection and the like for psychotic patients, and the working difficulty of medical personnel can be greatly reduced; besides, the specific microbial marker can be combined with a traditional psychological scale and other biomarkers to form a more comprehensive diagnosis mode, and revolutionary changes of prediction, diagnosis and treatment of schizophrenia with social anxiety disorder are expected to be brought.

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

Compositions and methods for treating psychosis or a psychotic disorder with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided. The compositions and methods may be used to improve one or more symptoms of psychosis or a psychotic disorder.or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.

The present invention relates to pyrazole derivatives and their applications, and relates to the field of chemical medicine. A compound as shown in formula I is provided, which acts on 5-HT 2A , 5‑HT 2C receptors for 5-HT 2A The selectivity is superior to or similar to that of pemasholin. It is used to treat behavioral disorders and psychosis associated with schizophrenia, Parkinson's disease, and dementia. The antipsychotic activity of the compound of the present application is comparable to that of pemasholin, and its cardiotoxicity is less than that of pemasholin. #imgabs0#

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The present application relates to a compound as shown in formula (I), stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, pharmaceutically acceptable salt or prodrug thereof, and preparation method and pharmaceutical composition. The compound is an NK-3 receptor antagonist, which can be used for preventing and / or treating depression, anxiety, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory disease, vomiting, preeclampsia, airway related disease, reproductive disorder, contraception and sex hormone dependent disease, gynecological disease related disease, menopausal syndrome related disease.

The invention provides application of a chalcone compound as well as a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicament for treating depression. The depression is selected from mild depression, moderate depression, severe depression, persistent depressive disorder, depression associated with bipolar disorder, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual anxiety disorder, encountering depression, pleasant sensation deficiency, melancholia, middle-year depression and late-year depression; depression caused by identifiable pressure factors, refractory depression, or a combination thereof. The compounds can treat mental symptoms of depression, such as depressive mood and loss of interest or fun in almost all activities.

The invention discloses an application of combination of nicotine and a second-generation antipsychotic in preparation of drugs for relieving bipolar depression, and belongs to the technical field of research and development of drugs for relieving bipolar depression. Experiments prove that compared with single use of nicotine and second-generation antipsychotic, the combined use of nicotine and second-generation antipsychotic in the invention has the advantages that the use amount of nicotine and second-generation antipsychotic is reduced; the nicotine and the second-generation antipsychotic have synergistic interaction in the aspect of improving manic behaviors of bipolar depression and have a better effect of improving bipolar depression, and the application of the combination of nicotine and the second-generation antipsychotic in preparation of the medicine for relieving bipolar depression provides experimental basis and scientific support for clinical treatment of bipolar depression.

Blood-based biomarkers involving evaluation of membrane protein clustering (MPC) on peripherally circulating lymphocytes can identify individuals experiencing depression, schizophrenia, or bipolar disorder, while differentiating those that will respond to treatment from those that will not respond to treatment within the depressed populations. These markers can help diagnose and treat depression, schizophrenia, or bipolar disorder. Further, this diagnostic tool can identify individuals with treatment-resistant depression earlier. The disclosed automated method improves the throughput of blood-based biomarkers and can be standardized across multiple sites of blood collection / analysis. The automated approach performs similarly to human scorers for each method of blood smear collection in accurately obtaining cluster size means for each sample.

The invention relates to the technical field of depression resistance, in particular to a pharmaceutical composition and application thereof. According to the application disclosed by the invention, low-dose non-addictive dose nicotine is combined with an antipsychotic drug such as olanzapine to investigate the influence of the nicotine on the bipolar depression, so that the treatment effect on the bipolar depression can be synergistically improved, and the side effect caused by the antipsychotic drug is reduced.